Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and doctor appointments.

Dr. Raphael Bueno

Dr. Raphael Bueno

Chief of the Division of Thoracic Surgery

Dr. Raphael Bueno is the Division of Thoracic Surgery chief at Brigham and Women’s Hospital in Boston and director of the renowned International Mesothelioma Program.

Get in touch
Jump to a Topic:

About Raphael Bueno

  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Top Doctor icon

    Top Doctor

  • Research Excellence icon

    Excellence in Research

  • Mesothelioma Pioneer icon

    Mesothelioma Pioneer

  • Team Leader icon

    Team Leader

  • Board Certified icon

    Board Certified in Surgery

  • Board Certified icon

    Board Certified in Thoracic Surgery

Get to Know Dr. Raphael Bueno

As the leader of the world’s most prestigious mesothelioma program, Dr. Raphael Bueno combines a thriving thoracic surgery practice with cutting-edge translational research that continues advancing mesothelioma treatment for patients.

Bueno serves as the senior surgeon at Dana-Farber Cancer Institute and a professor of surgery at Harvard Medical School, where he received his medical degree more than 30 years ago.

He assumed the leadership role in 2014 after serving as associate chief of thoracic surgery for more than a decade under mesothelioma treatment pioneer Dr. David Sugarbaker.

Bueno also is co-director of The Lung Center at Brigham and Women’s Hospital, helping build the program into one of the country’s most elite.

As part of a multidisciplinary treatment program at Brigham and Women’s, he performs aggressive surgery that can extend the lives of pleural mesothelioma patients significantly.

Specialties of Dr. Raphael Bueno

  • Mesothelioma and lung cancer

  • Pleurectomy and decortication surgery

  • Extrapleural pneumonectomy surgery

  • Esophageal cancer

  • Airway management and surgery

  • Pneumothorax

  • Tracheal disorders

  • Research

Dr. Raphael Bueno’s Experience and Medical Education

Awards and Other Recognitions

  • Boston Magazine Top Doctor, 2020

  • Castle Connolly America’s Top Doctors, 2020

  • Harvard Medical School, Henry Christian Award

  • America’s Top Doctors for Cancer

  • American Chemical Society Fellow

Mesothelioma Clinical Trials Under Raphael Bueno, MD

  • Phase I study using the drug combination of Keytruda (pembrolizumab) and defactinib prior to surgical resection. Bueno was part of an earlier mesothelioma clinical trial using defactinib, which is not yet approved by the U.S. Food and Drug Administration, alone before surgery.

  • Pleural mesothelioma prognostic biomarkers are being studied from prospectively collected pleural biopsies. The purpose of the study is part of an effort to improve cancer staging prior to surgery.

See More Top Mesothelioma Doctors

Following a Legend

It wasn’t easy following a mesothelioma treatment pioneer like Sugarbaker, who left in 2014 to build the Lung Institute at Baylor College of Medicine, but Bueno has flourished in his leadership role.

The Mesothelioma Program at Brigham and Women’s never has been better.

“Patients understand that it’s the whole program, and not just one individual that makes this the place to come for care,” he said. “It’s even better now.”

One of his ideas was designating every Friday as the day to handle mesothelioma patients exclusively. Bueno ensures his oncologists, surgeons, pathologists and radiologists all focus together on this rare and aggressive cancer.

“It’s an opportunity to really optimize the care for a lot of mesothelioma patients,” he said. “We’re working to make it the best for everyone.”

Publications of Dr. Raphael Bueno

  • Bueno, R. & Opitz, I. (2018) State of the Art review – Surgery in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology.

  • Bueno, R. et al. (2016). Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature Genetics.

  • Bueno R, et al. (2015). Validation of a molecular and pathological model for five-year mortality risk in patients with early-stage lung adenocarcinoma. Journal of Thoracic Oncology.

  • Bueno R, et al. (2010). Second generation sequencing of the mesothelioma tumor genome. PLoS ONE.

Disclaimer: Dr. Raphael Bueno has no professional affiliation with

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. Mesothelioma Packet

Get a Free Treatment Guide Sent Overnight

Get Yours Now

Find Ways to Pay for Treatment Costs

Get Started

Find an Active Mesothelioma Clinical Trial

Find Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

3 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. International Mesothelioma Program. (n.d.). Meet the IMP’s Leader.
    Retrieved from:
  2. Brigham and Women’s Hospital. (n.d.). Raphael Bueno, MD.
    Retrieved from:
  3. Dana-Farber. (n.d.). Raphael Bueno, MD. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified August 7, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now